HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Estee Lauder Companies’ Restructuring Targets Annual Savings Of $350M-$500M

Executive Summary

“The restructuring program is designed to right-size and streamline select areas within our organization,” which unfortunately means headcount reductions, CFO Tracey Travis said during the firm’s fiscal second quarter presentation. Lauder is projecting a return to organic sales growth in the third quarter and fourth quarter acceleration on the strength of innovation and strategic brand investments.

You may also be interested in...



Q4 Beauty Earnings Preview: China Volatility In 2023 Has Analysts Leery Of Big Beauty’s Results

Shiseido, L’Oreal and The Estee Lauder Companies are preparing to announce earnings results for the final three months of 2023, and all are expected to report headwinds that held back performance in China. Analysts anticipate a strong fourth quarter from Coty, which has been largely insulated from the ups and downs of the Chinese market in recent years.

Estee Lauder Companies, Among Industry’s ‘Long COVID’ Cases, Lowers FY 2024 Outlook

The Estee Lauder Companies says Asia travel retail will hammer fiscal 2024 full-year net sales, now expected to be down 2% to up 1%. A new profit recovery plan is designed to drive $800m-$1bn of incremental operating profit over the next two fiscal years, the New York-based firm said on 1 November.

Over The Counter 1 March 2024: The Emerging Benefits Of ‘Beauty-From-Within,’ Featuring Kenvue’s Paul LaTerra

In this episode of Over the Counter, HBW Insight speaks to Paul LaTerra, Director, R&D, Global Hair and Scalp for Kenvue, a New Jersey-based consumer health company that markets skin care brands Neutrogena, Aveeno and Lubriderm. We discuss growth of the beauty-from-within supplements market, how the products complement topical skin care and hair formulas and the growing body of research demonstrating significant skin and hair health benefits. 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154390

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel